Skip to NavigationSkip to content

News

0
Venclexta/Venclyxto (venetoclax) successfully met its primary endpoint in Phase 3 trials, providing prolonged, progression-free survival in chronic...
0
Janssen has announced that its psoriasis drug guselkumab has been awarded a positive opinion by the EMA’s Committee for Medicinal Products for...
0
Roche's Tecentriq has been added to the list of immunotherapy treatments placed on a partial hold by the FDA over safety concerns.
0
Teva announced last week that it had reached an agreement to sell Paragard, an intrauterine copper contraceptive, to CooperSurgical for $1.1 billion...

Features

The European Medicines Agency is on the cusp of rolling out one of the most ground-breaking digital platforms for facilitating collaboration and...